Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Clinical lung cancer | 2022-05-01 | PMID 34887192
Haratake Naoki, Hayashi Hidetoshi, Shimokawa Mototsugu and 9 more
